A Phase 3 interventional study of DTG + 3TC FDC in HIV Infections, sponsored by ViiV Healthcare. Completed at 8 sites in 3 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 44th largest by enrollment, is one of 8 that started in 2019, is one of 21 in phase 3, and was the 32nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 157th largest by enrollment of the 210 interventional ones that give a count, is one of 14 that started in 2019, is one of 65 in phase 3, and was the 194th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens. Thus, there is great interest from participants and clinicians in unique regimens that might avoid such toxicities by minimizing the number of antiretrovirals without sacrificing long-term antiviral efficacy. DTG plus 3TC is a novel, well-tolerated first-line regimen for HIV-infected treatment- naive participants, limiting the risk of many common adverse reactions associated with other antiretroviral drugs. This study was designed to evaluate the efficacy and safety of DTG/3TC as an FDC in ART-naive HIV-1-infected adolescents who weighed at least 25 kilograms (kg).
The study consisted of a Screening Phase (up to 28 days prior to the first dose of drug), followed by a Treatment Phase (up to 48 weeks). Participants who successfully completed 48 weeks of therapy and continued to receive benefit from DTG/3TC FDC were eligible to enter a 96-week Extension Phase. Study participants who successfully completed both the Treatment Phase through 48 weeks and the Extension Phase through 144 weeks and continued to receive benefit from this two-drug regimen were to continue receiving DTG/3TC FDC in a Continuation Phase (after Week 144) until DTG and 3TC were both locally approved for use as part of a dual regimen and the single entities of DTG and 3TC were available to participants (e.g., through public health services), or the DTG/3TC FDC tablet, if required by local regulations, was locally approved and available (e.g., commercially or through public health services), or the participant no longer derived clinical benefit, or the participant met a protocol-defined reason for discontinuation.
All participants received the FDC of DTG/3TC (50/300 milligrams) once daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received dolutegravir/lamivudine (DTG/3TC) (50/300 mg) Fixed Dose Combination (FDC) tablets orally once daily.
Drug: DTG + 3TC FDC
Drug pages: Dolutegravir · Lamivudine
DTG + 3TC FDC was available as a 50/300 mg tablet to be given orally once daily.
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 48 according to the Food and Drug Administration (FDA) snapshot algorithm.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 24
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.
Time frame: Week 24
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 96
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.
Time frame: Week 96
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 144
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 144 according to the FDA snapshot algorithm.
Time frame: Week 144
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.
Time frame: Week 24
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.
Time frame: Week 96
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 144 according to the FDA Snapshot algorithm.
Time frame: Week 144
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 48
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 48 according to the FDA snapshot algorithm.
Time frame: Week 48
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Through 144 Weeks
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A serious adverse event is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
Time frame: Up to 144 weeks
Number of Participants With AEs Through 144 Weeks by Severity
The Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. A higher grade indicates a greater severity.
Time frame: Up to 144 weeks
Number of Participants With Abnormal Findings for Hematology Parameters Through 144 Weeks
Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. The DAIDS criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 144 weeks
Number of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 144 Weeks
Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase (ALT), carbon dioxide, alkaline phosphatase, bilirubin, direct bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 144 weeks
Number of Participants With Abnormal Findings for Fasting Lipids Through 144 Weeks
Lipid assessments including cholesterol, low density lipoprotein (LDL) cholesterol, LDL Cholesterol Calculation, LDL Cholesterol Direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 144 weeks
Number of Participants With Abnormal Findings for Urinalysis Parameters Through 144 Weeks
Urine samples were collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 144 weeks
Number of Participants Who Discontinue Treatment Due to Adverse Events Through 144 Weeks
Time frame: Up to 144 weeks
Number of Participants With Adverse Events and Serious Adverse Events Through 96 Weeks
Time frame: Up to 96 weeks
Number of Participants With Severity of Adverse Events Through 96 Weeks
AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.
Time frame: Up to 96 weeks
Number of Participants With Abnormal Findings for Hematology Parameters Through 96 Weeks
Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 96 weeks
Number of Participants With Abnormal Findings for Clinical Chemistry Parameters Through 96 Weeks
Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 96 weeks
Number of Participants With Abnormal Findings for Fasting Lipids Through 96 Weeks
Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 96 weeks
Number of Participants With Abnormal Findings for Urinalysis Parameters Through 96 Weeks
Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Up to 96 weeks
Number of Participants Undergoing Viral Load Monitoring From Week 48 Through 144 Weeks
Viral load was defined as plasma HIV-RNA \<50 copies per mL. Viral load monitoring of participants was performed from Week 48 through 144 weeks.
Time frame: Weeks 48, 60, 72, 84, 96, 108, 120, 132, and 144
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Count at Weeks 24 and 48
Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline in CD8+ Cell Count at Weeks 24 and 48
Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Change From Baseline in Ratio of CD4+ and CD8+ at Weeks 24 and 48
Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 24 and 48
Number of Participants With Disease Progression From Week 24 Through Week 48
Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC.
Time frame: Week 24 and up to Week 48
Number of Participants With Any Adverse Events and Serious Adverse Events From Week 24 Through Week 48
Time frame: Week 24 and up to Week 48
Number of Participants With Severity of Adverse Events From Week 24 Through Week 48
AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.
Time frame: Week 24 and up to Week 48
Number of Participants With Abnormal Findings for Hematology Parameters From Week 24 Through Week 48
Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Week 24 and up to Week 48
Number of Participants With Abnormal Findings for Clinical Chemistry Parameters From Week 24 Through Week 48
Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Week 24 and up to Week 48
Number of Participants With Abnormal Findings for Fasting Lipids From Week 24 Through Week 48
Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Week 24 and up to Week 48
Number of Participants With Abnormal Findings for Urinalysis Parameters From Week 24 Through Week 48
Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
Time frame: Week 24 and up to Week 48
Number of Participants Who Discontinued Treatment Due to Adverse Events From Week 24 Through Week 48
Time frame: Week 24 and up to Week 48
Maximum Observed Plasma Concentration (Cmax) Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Time of Maximum Observed Plasma Concentration (Tmax) Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC[0-t]) Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Area Under the Curve (AUC) Over the Dosing Interval (AUC[0-tau]) Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Apparent Terminal Half-life (t1/2) Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: Pre-dose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 10, and 24 hours post-dose at Week 1
Observed Pre-dose Plasma Concentration Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: Pre-dose at Week 1
Observed Plasma Concentration at 24 Hours Following Dosing With DTG and 3TC
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
Time frame: 24 hours post-dose at Week 1
Number of Participants With Observed Genotypic Resistance to DTG and 3TC
Protocol-defined confirmed virologic withdrawal (CVW) through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no genotypic data were available for this participant at the time of virologic failure.
Time frame: Up to 144 weeks
Number of Participants With Observed Phenotypic Resistance to DTG and 3TC
Protocol-defined CVW through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no phenotypic data were available for this participant at the time of virologic failure.
Time frame: Up to 144 weeks
| Milestone | DTG/3TC FDC |
|---|---|
| Started | 32 |
| Completed | 20 |
| Not completed | 12 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Site closed | 5 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lack of efficacy | 1 |
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 48 according to the Food and Drug Administration (FDA) snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Less Than 50 Copies Per Milliliter (c/mL) at Week 48 | 81 (64 to 93) |
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 24 | 91 (75 to 98) |
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 96 | 69 (50 to 84) |
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 144 according to the FDA snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 144 | 66 (47 to 81) |
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 24 according to the FDA snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24 | 84 (67 to 95) |
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 96 according to the FDA snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96 | 69 (50 to 84) |
Percentage of participants with plasma HIV-1 RNA \<50 c/mL was assessed at Week 144 according to the FDA Snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144 | 66 (47 to 81) |
Percentage of participants with plasma HIV-1 RNA \<200 c/mL was assessed at Week 48 according to the FDA snapshot algorithm.
| Percentage of Participants | DTG/3TC FDC |
|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <200 c/mL at Week 48 | 84 (67 to 95) |
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A serious adverse event is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
| Participants | DTG/3TC FDC |
|---|---|
| AEs | 29 |
| SAEs | 5 |
The Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. A higher grade indicates a greater severity.
| Participants | DTG/3TC FDC |
|---|---|
| Grade 1 | 5 |
| Grade 2 | 19 |
| Grade 3 | 5 |
| Grade 4 | 0 |
| Grade 5 | 0 |
Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. The DAIDS criteria for grading the severity of adult and pediatric adverse events was used to assess severity. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Hemoglobin — Grade 1 | 0 |
| Hemoglobin — Grade 2 | 4 |
| Hemoglobin — Grade 3 | 0 |
| Hemoglobin — Grade 4 | 0 |
| Hemoglobin — Grade 0 | 28 |
| Leukocytes — Grade 1 | 2 |
| Leukocytes — Grade 2 | 0 |
| Leukocytes — Grade 3 | 0 |
| Leukocytes — Grade 4 | 0 |
| Leukocytes — Grade 0 | 30 |
| Neutrophils — Grade 1 | 0 |
| Neutrophils — Grade 2 | 1 |
| Neutrophils — Grade 3 | 0 |
| Neutrophils — Grade 4 | 0 |
| Neutrophils — Grade 0 | 31 |
Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase (ALT), carbon dioxide, alkaline phosphatase, bilirubin, direct bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Alanine Aminotransferase — Grade 1 | 3 |
| Alanine Aminotransferase — Grade 2 | 1 |
| Alanine Aminotransferase — Grade 3 | 0 |
| Alanine Aminotransferase — Grade 4 | 0 |
| Alanine Aminotransferase — Grade 0 | 28 |
| Alkaline Phosphatase — Grade 1 | 1 |
| Alkaline Phosphatase — Grade 2 | 2 |
| Alkaline Phosphatase — Grade 3 | 0 |
| Alkaline Phosphatase — Grade 4 | 0 |
| Alkaline Phosphatase — Grade 0 | 29 |
| Aspartate Aminotransferase — Grade 1 | 2 |
| Aspartate Aminotransferase — Grade 2 | 0 |
| Aspartate Aminotransferase — Grade 3 | 0 |
| Aspartate Aminotransferase — Grade 4 | 0 |
| Aspartate Aminotransferase — Grade 0 | 30 |
| Bilirubin — Grade 1 | 1 |
| Bilirubin — Grade 2 | 1 |
| Bilirubin — Grade 3 | 0 |
| Bilirubin — Grade 4 | 0 |
| Bilirubin — Grade 0 | 30 |
| Calcium — Grade 1 | 0 |
| Calcium — Grade 2 | 1 |
| Calcium — Grade 3 | 0 |
| Calcium — Grade 4 | 1 |
| Calcium — Grade 0 | 30 |
| Carbon Dioxide — Grade 1 | 17 |
| Carbon Dioxide — Grade 2 | 5 |
| Carbon Dioxide — Grade 3 | 0 |
| Carbon Dioxide — Grade 4 | 2 |
| Carbon Dioxide — Grade 0 | 8 |
| Creatine Kinase — Grade 1 | 2 |
| Creatine Kinase — Grade 2 | 2 |
| Creatine Kinase — Grade 3 | 2 |
| Creatine Kinase — Grade 4 | 0 |
| Creatine Kinase — Grade 0 | 26 |
| Creatinine — Grade 1 | 2 |
| Creatinine — Grade 2 | 0 |
| Creatinine — Grade 3 | 0 |
| Creatinine — Grade 4 | 0 |
| Creatinine — Grade 0 | 30 |
| Direct Bilirubin — Grade 1 | 0 |
| Direct Bilirubin — Grade 2 | 0 |
| Direct Bilirubin — Grade 3 | 1 |
| Direct Bilirubin — Grade 4 | 0 |
| Direct Bilirubin — Grade 0 | 31 |
| GFR from Creatinine Adjusted for BSA — Grade 1 | 0 |
| GFR from Creatinine Adjusted for BSA — Grade 2 | 14 |
| GFR from Creatinine Adjusted for BSA — Grade 3 | 5 |
| GFR from Creatinine Adjusted for BSA — Grade 4 | 0 |
| GFR from Creatinine Adjusted for BSA — Grade 0 | 13 |
| Potassium — Grade 1 | 2 |
| Potassium — Grade 2 | 0 |
| Potassium — Grade 3 | 0 |
| Potassium — Grade 4 | 0 |
| Potassium — Grade 0 | 30 |
| Sodium — Grade 1 | 6 |
| Sodium — Grade 2 | 1 |
| Sodium — Grade 3 | 0 |
| Sodium — Grade 4 | 0 |
| Sodium — Grade 0 | 25 |
Lipid assessments including cholesterol, low density lipoprotein (LDL) cholesterol, LDL Cholesterol Calculation, LDL Cholesterol Direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Cholesterol — Grade 1 | 7 |
| Cholesterol — Grade 2 | 1 |
| Cholesterol — Grade 3 | 0 |
| Cholesterol — Grade 4 | 0 |
| Cholesterol — Grade 0 | 24 |
| LDL Cholesterol — Grade 1 | 2 |
| LDL Cholesterol — Grade 2 | 0 |
| LDL Cholesterol — Grade 3 | 0 |
| LDL Cholesterol — Grade 4 | 0 |
| LDL Cholesterol — Grade 0 | 30 |
| LDL Cholesterol Calculation — Grade 1 | 2 |
| LDL Cholesterol Calculation — Grade 2 | 0 |
| LDL Cholesterol Calculation — Grade 3 | 0 |
| LDL Cholesterol Calculation — Grade 4 | 0 |
| LDL Cholesterol Calculation — Grade 0 | 30 |
| LDL Cholesterol Direct — Grade 1 | 6 |
| LDL Cholesterol Direct — Grade 2 | 3 |
| LDL Cholesterol Direct — Grade 3 | 0 |
| LDL Cholesterol Direct — Grade 4 | 0 |
| LDL Cholesterol Direct — Grade 0 | 23 |
| Triglycerides — Grade 1 | 5 |
| Triglycerides — Grade 2 | 0 |
| Triglycerides — Grade 3 | 0 |
| Triglycerides — Grade 4 | 0 |
| Triglycerides — Grade 0 | 27 |
Urine samples were collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Urinary Glucose — Grade 1 | 1 |
| Urinary Glucose — Grade 2 | 0 |
| Urinary Glucose — Grade 3 | 0 |
| Urinary Glucose — Grade 4 | 0 |
| Urinary Glucose — Grade 0 | 31 |
| Urinary Protein — Grade 1 | 5 |
| Urinary Protein — Grade 2 | 2 |
| Urinary Protein — Grade 3 | 0 |
| Urinary Protein — Grade 4 | 0 |
| Urinary Protein — Grade 0 | 25 |
| Urine Erythrocytes — Grade 1 | 2 |
| Urine Erythrocytes — Grade 2 | 0 |
| Urine Erythrocytes — Grade 3 | 0 |
| Urine Erythrocytes — Grade 4 | 0 |
| Urine Erythrocytes — Grade 0 | 30 |
| Participants | DTG/3TC FDC |
|---|---|
| Number of Participants Who Discontinue Treatment Due to Adverse Events Through 144 Weeks | 2 |
| Participants | DTG/3TC FDC |
|---|---|
| AEs | 29 |
| SAEs | 3 |
AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.
| Participants | DTG/3TC FDC |
|---|---|
| Grade 1 | 8 |
| Grade 2 | 19 |
| Grade 3 | 2 |
| Grade 4 | 0 |
| Grade 5 | 0 |
Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Hemoglobin — Grade 1 | 0 |
| Hemoglobin — Grade 2 | 4 |
| Hemoglobin — Grade 3 | 0 |
| Hemoglobin — Grade 4 | 0 |
| Hemoglobin — Grade 0 | 28 |
| Leukocytes — Grade 1 | 2 |
| Leukocytes — Grade 2 | 0 |
| Leukocytes — Grade 3 | 0 |
| Leukocytes — Grade 4 | 0 |
| Leukocytes — Grade 0 | 30 |
| Neutrophils — Grade 1 | 0 |
| Neutrophils — Grade 2 | 1 |
| Neutrophils — Grade 3 | 0 |
| Neutrophils — Grade 4 | 0 |
| Neutrophils — Grade 0 | 31 |
Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Alanine Aminotransferase — Grade 1 | 2 |
| Alanine Aminotransferase — Grade 2 | 1 |
| Alanine Aminotransferase — Grade 3 | 0 |
| Alanine Aminotransferase — Grade 4 | 0 |
| Alanine Aminotransferase — Grade 0 | 29 |
| Alkaline Phosphatase — Grade 1 | 1 |
| Alkaline Phosphatase — Grade 2 | 2 |
| Alkaline Phosphatase — Grade 3 | 0 |
| Alkaline Phosphatase — Grade 4 | 0 |
| Alkaline Phosphatase — Grade 0 | 29 |
| Aspartate Aminotransferase — Grade 1 | 2 |
| Aspartate Aminotransferase — Grade 2 | 0 |
| Aspartate Aminotransferase — Grade 3 | 0 |
| Aspartate Aminotransferase — Grade 4 | 0 |
| Aspartate Aminotransferase — Grade 0 | 30 |
| Bilirubin — Grade 1 | 2 |
| Bilirubin — Grade 2 | 0 |
| Bilirubin — Grade 3 | 0 |
| Bilirubin — Grade 4 | 0 |
| Bilirubin — Grade 0 | 30 |
| Calcium — Grade 1 | 0 |
| Calcium — Grade 2 | 1 |
| Calcium — Grade 3 | 0 |
| Calcium — Grade 4 | 1 |
| Calcium — Grade 0 | 30 |
| Carbon Dioxide — Grade 1 | 14 |
| Carbon Dioxide — Grade 2 | 5 |
| Carbon Dioxide — Grade 3 | 0 |
| Carbon Dioxide — Grade 4 | 2 |
| Carbon Dioxide — Grade 0 | 11 |
| Creatine Kinase — Grade 1 | 2 |
| Creatine Kinase — Grade 2 | 1 |
| Creatine Kinase — Grade 3 | 2 |
| Creatine Kinase — Grade 4 | 0 |
| Creatine Kinase — Grade 0 | 27 |
| Creatinine — Grade 1 | 2 |
| Creatinine — Grade 2 | 0 |
| Creatinine — Grade 3 | 0 |
| Creatinine — Grade 4 | 0 |
| Creatinine — Grade 0 | 30 |
| GFR from Creatinine Adjusted for BSA — Grade 1 | 0 |
| GFR from Creatinine Adjusted for BSA — Grade 2 | 13 |
| GFR from Creatinine Adjusted for BSA — Grade 3 | 5 |
| GFR from Creatinine Adjusted for BSA — Grade 4 | 0 |
| GFR from Creatinine Adjusted for BSA — Grade 0 | 14 |
| Potassium — Grade 1 | 2 |
| Potassium — Grade 2 | 0 |
| Potassium — Grade 3 | 0 |
| Potassium — Grade 4 | 0 |
| Potassium — Grade 0 | 30 |
| Sodium — Grade 1 | 5 |
| Sodium — Grade 2 | 1 |
| Sodium — Grade 3 | 0 |
| Sodium — Grade 4 | 0 |
| Sodium — Grade 0 | 26 |
Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Cholesterol — Grade 1 | 7 |
| Cholesterol — Grade 2 | 1 |
| Cholesterol — Grade 3 | 0 |
| Cholesterol — Grade 4 | 0 |
| Cholesterol — Grade 0 | 24 |
| LDL Cholesterol — Grade 1 | 2 |
| LDL Cholesterol — Grade 2 | 0 |
| LDL Cholesterol — Grade 3 | 0 |
| LDL Cholesterol — Grade 4 | 0 |
| LDL Cholesterol — Grade 0 | 30 |
| LDL Cholesterol Calculation — Grade 1 | 1 |
| LDL Cholesterol Calculation — Grade 2 | 0 |
| LDL Cholesterol Calculation — Grade 3 | 0 |
| LDL Cholesterol Calculation — Grade 4 | 0 |
| LDL Cholesterol Calculation — Grade 0 | 31 |
| LDL Cholesterol Direct — Grade 1 | 6 |
| LDL Cholesterol Direct — Grade 2 | 2 |
| LDL Cholesterol Direct — Grade 3 | 0 |
| LDL Cholesterol Direct — Grade 4 | 0 |
| LDL Cholesterol Direct — Grade 0 | 24 |
| Triglycerides — Grade 1 | 4 |
| Triglycerides — Grade 2 | 0 |
| Triglycerides — Grade 3 | 0 |
| Triglycerides — Grade 4 | 0 |
| Triglycerides — Grade 0 | 28 |
Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 0 - no abnormality; Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Urinary Glucose — Grade 1 | 1 |
| Urinary Glucose — Grade 2 | 0 |
| Urinary Glucose — Grade 3 | 0 |
| Urinary Glucose — Grade 4 | 0 |
| Urinary Glucose — Grade 0 | 31 |
| Urinary Protein — Grade 1 | 3 |
| Urinary Protein — Grade 2 | 2 |
| Urinary Protein — Grade 3 | 0 |
| Urinary Protein — Grade 4 | 0 |
| Urinary Protein — Grade 0 | 27 |
| Urine Erythrocytes — Grade 1 | 2 |
| Urine Erythrocytes — Grade 2 | 0 |
| Urine Erythrocytes — Grade 3 | 0 |
| Urine Erythrocytes — Grade 4 | 0 |
| Urine Erythrocytes — Grade 0 | 30 |
Viral load was defined as plasma HIV-RNA \<50 copies per mL. Viral load monitoring of participants was performed from Week 48 through 144 weeks.
| Participants | DTG/3TC FDC |
|---|---|
| Week 48 | 28 |
| Week 60 | 27 |
| Week 72 | 23 |
| Week 84 | 23 |
| Week 96 | 23 |
| Week 108 | 21 |
| Week 120 | 21 |
| Week 132 | 21 |
| Week 144 | 21 |
Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^6 cells per liter | DTG/3TC FDC |
|---|---|
| Baseline (Day 1) | 371.500 (270.00 to 507.50) |
| Week 24 | 167.000 (103.00 to 319.00) |
| Week 48 | 223.500 (85.50 to 380.50) |
Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.
| 10^6 cells per liter | DTG/3TC FDC |
|---|---|
| Baseline (Day 1) | 828.000 (679.50 to 1031.50) |
| Week 24 | -15.000 (-117.00 to 301.00) |
| Week 48 | -78.500 (-243.00 to 176.00) |
Baseline value was defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value.
| Ratio | DTG/3TC FDC |
|---|---|
| Baseline (Day 1) | 0.395 (0.33 to 0.64) |
| Week 24 | 0.215 (0.14 to 0.30) |
| Week 48 | 0.345 (0.24 to 0.49) |
Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC.
| Participants | DTG/3TC FDC |
|---|---|
| Week 24 | 0 |
| Week 48 | 1 |
| Participants | DTG/3TC FDC |
|---|---|
| AEs (Week 24) | 23 |
| AEs (Week 48) | 28 |
| SAEs (Week 24) | 1 |
| SAEs (Week 48) | 2 |
AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences; Grade 5 - death. The higher the grade, the more severe the symptoms.
| Participants | DTG/3TC FDC |
|---|---|
| Grade 1 (Week 24) | 9 |
| Grade 2 (Week 24) | 13 |
| Grade 3 (Week 24) | 1 |
| Grade 4 (Week 24) | 0 |
| Grade 5 (Week 24) | 0 |
| Grade 1 (Week 48) | 11 |
| Grade 2 (Week 48) | 16 |
| Grade 3 (Week 48) | 1 |
| Grade 4 (Week 48) | 0 |
| Grade 5 (Week 48) | 0 |
Blood samples were collected from participants for analysis of hematology parameters including hemoglobin, leukocytes and neutrophils. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Hemoglobin - Grade 1 (Week 24) | 0 |
| Hemoglobin - Grade 2 (Week 24) | 2 |
| Hemoglobin - Grade 3 (Week 24) | 0 |
| Hemoglobin - Grade 4 (Week 24) | 0 |
| Leukocytes - Grade 1 (Week 24) | 1 |
| Leukocytes - Grade 2 (Week 24) | 0 |
| Leukocytes - Grade 3 (Week 24) | 0 |
| Leukocytes - Grade 4 (Week 24) | 0 |
| Neutrophils - Grade 1 (Week 24) | 0 |
| Neutrophils - Grade 2 (Week 24) | 1 |
| Neutrophils - Grade 3 (Week 24) | 0 |
| Neutrophils - Grade 4 (Week 24) | 0 |
| Hemoglobin - Grade 1 (Week 48) | 0 |
| Hemoglobin - Grade 2 (Week 48) | 2 |
| Hemoglobin - Grade 3 (Week 48) | 0 |
| Hemoglobin - Grade 4 (Week 48) | 0 |
| Leukocytes - Grade 1 (Week 48) | 2 |
| Leukocytes - Grade 2 (Week 48) | 0 |
| Leukocytes - Grade 3 (Week 48) | 0 |
| Leukocytes - Grade 4 (Week 48) | 0 |
| Neutrophils - Grade 1 (Week 48) | 0 |
| Neutrophils - Grade 2 (Week 48) | 1 |
| Neutrophils - Grade 3 (Week 48) | 0 |
| Neutrophils - Grade 4 (Week 48) | 0 |
Blood samples were collected from participants for analysis of clinical chemistry parameters including potassium, aspartate aminotransferase, creatinine, alanine aminotransferase, carbon dioxide, alkaline phosphatase, bilirubin, sodium, GFR from creatinine adjusted for BSA, calcium, and creatine kinase. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Alanine Aminotransferase - Grade 1 (Week 24) | 1 |
| Alanine Aminotransferase - Grade 2 (Week 24) | 0 |
| Alanine Aminotransferase - Grade 3 (Week 24) | 0 |
| Alanine Aminotransferase - Grade 4 (Week 24) | 0 |
| Alkaline Phosphatase - Grade 1 (Week 24) | 1 |
| Alkaline Phosphatase - Grade 2 (Week 24) | 2 |
| Alkaline Phosphatase - Grade 3 (Week 24) | 0 |
| Alkaline Phosphatase - Grade 4 (Week 24) | 0 |
| Aspartate Aminotransferase - Grade 1 (Week 24) | 1 |
| Aspartate Aminotransferase - Grade 2 (Week 24) | 0 |
| Aspartate Aminotransferase - Grade 3 (Week 24) | 0 |
| Aspartate Aminotransferase - Grade 4 (Week 24) | 0 |
| Bilirubin - Grade 1 (Week 24) | 1 |
| Bilirubin - Grade 2 (Week 24) | 0 |
| Bilirubin - Grade 3 (Week 24) | 0 |
| Bilirubin - Grade 4 (Week 24) | 0 |
| Calcium - Grade 1 (Week 24) | 0 |
| Calcium - Grade 2 (Week 24) | 1 |
| Calcium - Grade 3 (Week 24) | 0 |
| Calcium - Grade 4 (Week 24) | 1 |
| Carbon Dioxide - Grade 1 (Week 24) | 11 |
| Carbon Dioxide - Grade 2 (Week 24) | 4 |
| Carbon Dioxide - Grade 3 (Week 24) | 0 |
| Carbon Dioxide - Grade 4 (Week 24) | 2 |
| Creatine Kinase - Grade 1 (Week 24) | 1 |
| Creatine Kinase - Grade 2 (Week 24) | 0 |
| Creatine Kinase - Grade 3 (Week 24) | 0 |
| Creatine Kinase - Grade 4 (Week 24) | 0 |
| Creatinine - Grade 1 (Week 24) | 1 |
| Creatinine - Grade 2 (Week 24) | 0 |
| Creatinine - Grade 3 (Week 24) | 0 |
| Creatinine - Grade 4 (Week 24) | 0 |
| GFR from Creatinine Adjusted for BSA - Grade 1 (Week 24) | 0 |
| GFR from Creatinine Adjusted for BSA - Grade 2 (Week 24) | 12 |
| GFR from Creatinine Adjusted for BSA - Grade 3 (Week 24) | 3 |
| GFR from Creatinine Adjusted for BSA - Grade 4 (Week 24) | 0 |
| Potassium - Grade 1 (Week 24) | 1 |
| Potassium - Grade 2 (Week 24) | 0 |
| Potassium - Grade 3 (Week 24) | 0 |
| Potassium - Grade 4 (Week 24) | 0 |
| Sodium - Grade 1 (Week 24) | 5 |
| Sodium - Grade 2 (Week 24) | 1 |
| Sodium - Grade 3 (Week 24) | 0 |
| Sodium - Grade 4 (Week 24) | 0 |
| Alanine Aminotransferase - Grade 1 (Week 48) | 1 |
| Alanine Aminotransferase - Grade 2 (Week 48) | 0 |
| Alanine Aminotransferase - Grade 3 (Week 48) | 0 |
| Alanine Aminotransferase - Grade 4 (Week 48) | 0 |
| Alkaline Phosphatase - Grade 1 (Week 48) | 1 |
| Alkaline Phosphatase - Grade 2 (Week 48) | 2 |
| Alkaline Phosphatase - Grade 3 (Week 48) | 0 |
| Alkaline Phosphatase - Grade 4 (Week 48) | 0 |
| Aspartate Aminotransferase - Grade 1 (Week 48) | 1 |
| Aspartate Aminotransferase - Grade 2 (Week 48) | 0 |
| Aspartate Aminotransferase - Grade 3 (Week 48) | 0 |
| Aspartate Aminotransferase - Grade 4 (Week 48) | 0 |
| Bilirubin - Grade 1 (Week 48) | 1 |
| Bilirubin - Grade 2 (Week 48) | 0 |
| Bilirubin - Grade 3 (Week 48) | 0 |
| Bilirubin - Grade 4 (Week 48) | 0 |
| Calcium - Grade 1 (Week 48) | 0 |
| Calcium - Grade 2 (Week 48) | 1 |
| Calcium - Grade 3 (Week 48) | 0 |
| Calcium - Grade 4 (Week 48) | 1 |
| Carbon Dioxide - Grade 1 (Week 48) | 12 |
| Carbon Dioxide - Grade 2 (Week 48) | 5 |
| Carbon Dioxide - Grade 3 (Week 48) | 0 |
| Carbon Dioxide - Grade 4 (Week 48) | 2 |
| Creatine Kinase - Grade 1 (Week 48) | 1 |
| Creatine Kinase - Grade 2 (Week 48) | 0 |
| Creatine Kinase - Grade 3 (Week 48) | 0 |
| Creatine Kinase - Grade 4 (Week 48) | 0 |
| Creatinine - Grade 1 (Week 48) | 2 |
| Creatinine - Grade 2 (Week 48) | 0 |
| Creatinine - Grade 3 (Week 48) | 0 |
| Creatinine - Grade 4 (Week 48) | 0 |
| GFR from Creatinine Adjusted for BSA - Grade 1 (Week 48) | 0 |
| GFR from Creatinine Adjusted for BSA - Grade 2 (Week 48) | 13 |
| GFR from Creatinine Adjusted for BSA - Grade 3 (Week 48) | 6 |
| GFR from Creatinine Adjusted for BSA - Grade 4 (Week 48) | 0 |
| Potassium - Grade 1 (Week 48) | 1 |
| Potassium - Grade 2 (Week 48) | 0 |
| Potassium - Grade 3 (Week 48) | 0 |
| Potassium - Grade 4 (Week 48) | 0 |
| Sodium - Grade 1 (Week 48) | 5 |
| Sodium - Grade 2 (Week 48) | 1 |
| Sodium - Grade 3 (Week 48) | 0 |
| Sodium - Grade 4 (Week 48) | 0 |
Lipid assessments including cholesterol, LDL cholesterol, LDL cholesterol calculation, LDL cholesterol direct, and triglycerides were performed. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Cholesterol - Grade 1 (Week 24) | 2 |
| Cholesterol - Grade 2 (Week 24) | 0 |
| Cholesterol - Grade 3 (Week 24) | 0 |
| Cholesterol - Grade 4 (Week 24) | 0 |
| LDL cholesterol - Grade 1 (Week 24) | 1 |
| LDL cholesterol - Grade 2 (Week 24) | 0 |
| LDL cholesterol - Grade 3 (Week 24) | 0 |
| LDL cholesterol - Grade 4 (Week 24) | 0 |
| Triglycerides - Grade 1 (Week 24) | 1 |
| Triglycerides - Grade 2 (Week 24) | 0 |
| Triglycerides - Grade 3 (Week 24) | 0 |
| Triglycerides - Grade 4 (Week 24) | 0 |
| Cholesterol - Grade 1 (Week 48) | 5 |
| Cholesterol - Grade 2 (Week 48) | 1 |
| Cholesterol - Grade 3 (Week 48) | 0 |
| Cholesterol - Grade 4 (Week 48) | 0 |
| LDL cholesterol - Grade 1 (Week 48) | 1 |
| LDL cholesterol - Grade 2 (Week 48) | 0 |
| LDL cholesterol - Grade 3 (Week 48) | 0 |
| LDL cholesterol - Grade 4 (Week 48) | 0 |
| Triglycerides - Grade 1 (Week 48) | 1 |
| Triglycerides - Grade 2 (Week 48) | 0 |
| Triglycerides - Grade 3 (Week 48) | 0 |
| Triglycerides - Grade 4 (Week 48) | 0 |
Urine samples will be collected from participants for the analysis of urinalysis parameters including urinary glucose, urinary protein, and urine erythrocytes. Grades were defined based on numeric criteria as follows: Grade 1 - mild; Grade 2 - moderate; Grade 3 - severe or medically significant; Grade 4 - life-threatening consequences.
| Participants | DTG/3TC FDC |
|---|---|
| Urinary Glucose - Grade 1 (Week 24) | 0 |
| Urinary Glucose - Grade 2 (Week 24) | 0 |
| Urinary Glucose - Grade 3 (Week 24) | 0 |
| Urinary Glucose - Grade 4 (Week 24) | 0 |
| Urinary Protein - Grade 1 (Week 24) | 0 |
| Urinary Protein - Grade 2 (Week 24) | 0 |
| Urinary Protein - Grade 3 (Week 24) | 0 |
| Urinary Protein - Grade 4 (Week 24) | 0 |
| Urinary Glucose - Grade 1 (Week 48) | 1 |
| Urinary Glucose - Grade 2 (Week 48) | 0 |
| Urinary Glucose - Grade 3 (Week 48) | 0 |
| Urinary Glucose - Grade 4 (Week 48) | 0 |
| Urinary Protein - Grade 1 (Week 48) | 1 |
| Urinary Protein - Grade 2 (Week 48) | 1 |
| Urinary Protein - Grade 3 (Week 48) | 0 |
| Urinary Protein - Grade 4 (Week 48) | 0 |
| Participants | DTG/3TC FDC |
|---|---|
| Week 24 | 1 |
| Week 48 | 1 |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| Nanogram per milliliter (ng/mL) | DTG/3TC FDC |
|---|---|
| Maximum observed plasma concentration - DTG | 5354.870 ± 25.02 |
| Maximum observed plasma concentration - 3TC | 2778.555 ± 27.80 |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| Hours | DTG/3TC FDC |
|---|---|
| Time of maximum observed plasma concentration - DTG | 2.000 (1.00 to 3.00) |
| Time of maximum observed plasma concentration - 3TC | 1.000 (1.00 to 3.00) |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| hours*nanogram per milliliter (h*ng/mL) | DTG/3TC FDC |
|---|---|
| AUC[0-t] - DTG | 74001.76 ± 23.2 |
| AUC[0-t] - 3TC | 12277.62 ± 17.7 |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| hours*nanogram per milliliter (h*ng/mL) | DTG/3TC FDC |
|---|---|
| AUC[0-tau] - DTG | 74001.76 ± 23.2 |
| AUC[0-tau] - 3TC | 12277.62 ± 17.7 |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| Hours | DTG/3TC FDC |
|---|---|
| Apparent terminal half-life - DTG | 12.910 ± 15.35 |
| Apparent terminal half-life - 3TC | 4.823 ± 13.26 |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| ng/mL | DTG/3TC FDC |
|---|---|
| DTG | 1636.791 ± 39.26 |
| 3TC | 51.073 ± 60.88 |
Blood samples were collected on a subset of participants for intensive pharmacokinetic analysis.
| ng/mL | DTG/3TC FDC |
|---|---|
| DTG | 1635.606 ± 25.36 |
| 3TC | 53.453 ± 33.42 |
Protocol-defined confirmed virologic withdrawal (CVW) through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no genotypic data were available for this participant at the time of virologic failure.
| Participants | DTG/3TC FDC |
|---|---|
| Number of Participants With Observed Genotypic Resistance to DTG and 3TC | 0 |
Protocol-defined CVW through Week 144 was low with 1 participant meeting CVW criteria. Resistance testing failed, and therefore no phenotypic data were available for this participant at the time of virologic failure.
| Participants | DTG/3TC FDC |
|---|---|
| Number of Participants With Observed Phenotypic Resistance to DTG and 3TC | 0 |
Collected over All-Cause mortality, Non-SAEs and SAEs were collected from Day 1 up to Week 144. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG/3TC FDC | 0/32 (0%) | 5/32 (15.6%) | 29/32 (90.6%) |
| Event | DTG/3TC FDC |
|---|---|
| Anal abscessInfections and infestations | 1/32 |
| Vulvovaginal wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/32 |
| OrchitisInfections and infestations | 1/32 |
| Ulcerative keratitisEye disorders | 1/32 |
| Postoperative wound complicationInjury, poisoning and procedural complications | 1/32 |
| Major depressionPsychiatric disorders | 1/32 |
| Event | DTG/3TC FDC |
|---|---|
| COVID-19Infections and infestations | 10/32 |
| NasopharyngitisInfections and infestations | 8/32 |
| Upper respiratory tract infectionInfections and infestations | 6/32 |
| PharyngitisInfections and infestations | 5/32 |
| HeadacheNervous system disorders | 4/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/32 |
| FolliculitisInfections and infestations | 3/32 |
| TonsillitisInfections and infestations | 3/32 |
| Secondary syphilisInfections and infestations | 3/32 |
| Influenza like illnessGeneral disorders | 3/32 |
| Age, Continuous(Years) | DTG/3TC FDC |
|---|---|
| Mean | 16.0 ± 1.27 |
| Sex: Female, Male(Participants) | DTG/3TC FDC |
|---|---|
| Female | 11 |
| Male | 21 |
| Race/Ethnicity, Customized(Participants) | DTG/3TC FDC |
|---|---|
| African American/African Heritage | 13 |
| Asian - South East Asian Heritage | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.viiv-studyregister.com
Ran from May 2019 to primary completion in Dec 2021, 30 months.
Results were first posted in Aug 2022, 8 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 30 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dolutegravir · Lamivudine